Neuland Laboratories Ltd (NSE:NEULANDLAB)

Q1 2027 Neuland Laboratories Ltd Earnings Call Transcript

Aug 5, 2026 / 12:00 PM GMT

Release Date Price: ₹19956 (+3.54%)

Transcript

Key Points

Positve

Neuland Laboratories Ltd (BOM:524558) reported a strong Q1 FY27 with total income growing 116.3% year-over-year to ₹650.1 crores, driven primarily by commercial CMS projects.
EBITDA margin improved significantly to 35.5% in Q1 FY27, supported by a higher revenue base, operating leverage, and a favorable customer mix.
Working capital efficiency improved substantially, with working capital days reduced from 137 days at the end of FY26 to 84 days in Q1 FY27.
The company's peptide manufacturing facility is set to be commissioned next month, and management expects Module 1 to be fully occupied with a pipeline of projects, potentially activating Module 2 during the year.
Management expressed increased confidence in the development pipeline, noting a couple of new advanced clinical projects, including peptide projects, which pave the way for larger volumes in the future.
The strategic collaboration with Gland Pharma creates a differentiated platform in sterile APIs, combining complementary strengths and demonstrating commitment to the specialty GDS business.

Negative

Management reiterated the inherent uneven nature of the business, cautioning that quarterly performance should be assessed over a longer period rather than through a single quarter.
Commercial CMS growth is driven by only a handful of molecules (approximately three), which are subject to volatility and lumpiness in ordering patterns.
The company is entering a phase of higher capital expenditure, with a cash outflow of ₹121.6 crores in Q1 FY27 and additional approved investments of ₹203 crores, which could pressure return on capital in the near term.
Management noted that the favorable EBITDA margin of 35.5% was partly due to favorable exchange rates and a favorable product mix, and they continue to guide towards a long-term 25%+ EBITDA margin, implying current levels may not be sustainable.
The company faces potential risks from evolving geopolitical developments and broader global trade dynamics, which could impact supply chain continuity and customer commitments, although no material impact has been experienced so far.
Development revenue remains lumpy and product-specific, and management was reluctant to provide quantitative guidance, making it difficult to predict the timing and scale of future commercial conversions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NEUL.NS - Neuland Laboratories Ltd
Q1 2027 Neuland Laboratories Ltd Earnings Call
Aug 05, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Newland Laborities Limited Q1 NFY27 earning conference call.

As a reminder. All participant line will be in the listen-only mode and there will be an opportunity for you to ask question after the presentation conclude. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch tone phone. Please note that this conference is being recorded. I now hand the conference over to Miss Ranjun Jain from ENY.

Thank you and over to you ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.